Understanding COVID‐19 Risk in Patients With Immune‐Mediated Inflammatory Diseases: A Population‐Based Analysis of SARS–CoV‐2 Testing
Main finding · At least 1 SARS-CoV-2 testResult — go to the resultOdds ratio 1.20 95% CI 1.19–1.21Authors' conclusion
Patients across all IMIDs were more likely to be tested for SARS-CoV-2 versus those without IMIDs. The risk of SARS-CoV-2 infection varied across disease subgroups.
Study context
- Population
- Adult residents of Ontario, Canada, January 2020 to December 2020matched cohort
- Participants
- 493,499 vs 2,466,946
- Exposure
- Immune-mediated inflammatory disease (IMID) patients vs matched non-IMID comparators from the general population
- IMIDn = 493,499
- Non-IMIDn = 2,466,946reference
- Outcome
- Incidence of SARS-CoV-2 testing and infection
Methodological detailsmatched 1:5 on sociodemographic factors, multivariable logistic regression
- Matched 1:5 on sociodemographic factors
- Multivariable logistic regression
Main finding
At least 1 SARS-CoV-2 test
Odds ratio
1.20
95% CI 1.19–1.21
By group
IMIDvs Non-IMID
OR 1.20 (95% CI 1.19–1.21)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Testing positive for SARS-CoV-2
Testing positive for SARS-CoV-2
- Proportion testing positive identical in both groups
Odds of SARS-CoV-2 infection by IMID group
- Varied across IMID groups; not significantly elevated for most IMID groups vs non-IMID comparators
- Lower in inflammatory bowel disease (IBD) and multiple sclerosis (MS); marginally higher in rheumatoid arthritis (RA) and iritis
Original publication
Understanding COVID‐19 Risk in Patients With Immune‐Mediated Inflammatory Diseases: A Population‐Based Analysis of SARS–CoV‐2 Testing. Arthritis Care Res (Hoboken). Published 27 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →